Monday, November 2, 2026

Back to today

BMRN Earnings Review

BioMarin’s Q3 revenue rose 32% to $1.02 billion after the Amicus acquisition, while lower 2026 guidance and $2.8 billion of net debt weighed on earnings.

From X

@kevin__mak

Kevin Mak on X

$ASTS So many questions about ASTS (please don't reply to unrelated threads to get my attention, just DM me). I have no position in the company. My comments from 3+ quarters ago is that I wanted to see "more metal in space". My concern from 5+ quarters ago was "how do they go from producing 1 satellite in 6 months, to 6 satellites per month, that's a really hard scaling problem". I think Starlink screwed up with their Swarm acquisition and trying to force that tech to work, it put a 18+ month delay on them. My hope was that ASTS would capitalize on that, and it generally appears that they've had scaling issues that prevented that from happening. That isn't really their fault, "space is hard" and "mass production is different from prototypes". I think money isn't a problem for them, they have so much cash (they were smart to take advantage of their high stock price). The problem is execution is hard even if you have lots of cash. Strategically they're in a good place, the MNO's definitely want/need them to work to compete w/ Starlink. But the MNO's are powerless, they're awful at execution (they're only good at increasing your monthly bill!). The BO failure was a really big problem. SpaceX (Starlink) had very little leverage on ASTS before. If they slowroll/deny F9 launches, they just push ASTS towards their competitor (BO). Two competitors (BO and ASTS) become stronger. But since BO was offline, it makes SpaceX the de facto monopolist to ASTS' launch. That gives them a ton of power in this situation and I imagine (but have no way to prove it), they would flex that competitive pressure on the company. That's not illegal anti-competitive behavior, that's just "pressure". It's a tricky set of problems that face the company and the stock price reflects that. I don't have a strong view in either direction of whether things get better or worse from here. But my initial hopes/thesis were steadily eroded by the execution issues (and valuation), hence my eventual exit from my long position. I don't think I'm saying anything thoughtful or what people don't already know/experience. But worth putting it out there because I've received _a lot_ of questions. Disclosure: No position in ASTS.

Altria: Dutiful

Altria raised 2026 adjusted EPS guidance to $5.66 to $5.74 and authorized more buybacks, while on! loses share as cigarette margins hold.

BR · long

Broadridge Financial Solutns

Broadridge Financial Solutions is framed as a high and rising free-cash-flow generator at a depressed valuation, with insider buying…

FTAI 3Q26: Aero margins in focus

FTAI’s Aerospace Products margin rebounded to 31% as CFM56 module output rose, while Power deposits and contracted deliveries fund its 2027…

CVX Earnings Review

Chevron’s Q3 revenue rose 35% to $65.2 billion and EBITDA 75% to $20.2 billion, while production trailed guidance and refining margins…

SNY Earnings Review

Sanofi raised FY26 guidance after Q3 sales grew 14.3% at constant currency, led by 34.8% Dupixent growth; vaccines declined 6.6%.

TSOH Weekly Roundup (10/30/2026)

Markel spent $315 million repurchasing shares in Q3 as Thrive agreed to buy ADT for $7.6 billion and Hasbro cited rising adult toy demand.

Publications we follow

Every publication on this site, hand-picked.

129 publications

Newsletters 109

X accounts we follow

Every account on this site, hand-picked.

91 accounts

Investor letters we follow

303 firms

Sectors

Ordered by how often our editor reaches for them.